Literature DB >> 24379604

Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Edoardo G Giannini1, Alessandro Cucchetti1, Virginia Erroi1, Francesca Garuti1, Federica Odaldi1, Franco Trevisani1.   

Abstract

Surveillance for hepatocellular carcinoma (HCC) is considered a standard of care for patients with chronic liver disease who are at risk of developing this malignancy. Several studies have shown that surveillance can improve the prognosis of patients diagnosed with HCC through an increased likelihood of application of curative or effective treatments. Repetition of liver ultrasonography (US) every 6 mo is the recommended surveillance program to detect early HCCs, and a positive US has to entrain a well-defined recall policy based on contrast-enhanced, dynamic radiological imaging or biopsy for the diagnosis of HCC. Although HCC fulfills the accepted criteria regarding cost-effective cancer screening and surveillance, the implementation of surveillance in clinical practice is defective and this has a negative impact on the cost-effectiveness of the procedure. Education of both physicians and patients is of paramount importance in order to improve the surveillance application and its benefits in patients at risk of HCC. The promotion of specific educational programs for practitioners, clinicians and patients is instrumental in order to expand the correct use of surveillance in clinical practice and eventually improve HCC prognosis.

Entities:  

Keywords:  Cost-effectiveness; Hepatocellular carcinoma; Screening; Surveillance; Ultrasonography

Mesh:

Year:  2013        PMID: 24379604      PMCID: PMC3870532          DOI: 10.3748/wjg.v19.i47.8808

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  122 in total

1.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

Review 2.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

Authors:  Donald Poon; Benjamin O Anderson; Li-Tzong Chen; Koichi Tanaka; Wan Yee Lau; Eric Van Cutsem; Harjit Singh; Wan Cheng Chow; London Lucien Ooi; Pierce Chow; Maung Win Khin; Wen Hsin Koo
Journal:  Lancet Oncol       Date:  2009-11       Impact factor: 41.316

3.  Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients.

Authors:  C K Kim; J H Lim; W J Lee
Journal:  J Ultrasound Med       Date:  2001-02       Impact factor: 2.153

4.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

5.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

7.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 8.  Impact of therapy on the outcome of chronic hepatitis B.

Authors:  Yun-Fan Liaw
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

9.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  18 in total

1.  Capsule commentary on Larochelle et al., Reducing excess biomarker testing at an academic medical center.

Authors:  Sarah Augustine
Journal:  J Gen Intern Med       Date:  2014-11       Impact factor: 5.128

2.  Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein.

Authors:  Edoardo G Giannini; Franco Trevisani
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

3.  Hepatocellular carcinoma surveillance: an open question.

Authors:  Maurizio Biselli; Francesca Garuti; Andrea Neri
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Authors:  Edoardo G Giannini; Alessandro Moscatelli; Gaia Pellegatta; Alessandro Vitale; Fabio Farinati; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Rodolfo Sacco; Filomena Morisco; Gabriele Missale; Francesco Giuseppe Foschi; Antonio Gasbarrini; Gianluca Svegliati Baroni; Roberto Virdone; Alberto Masotto; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

5.  Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

Authors:  Andrea Marcellusi; Raffaella Viti; Francesco Damele; Calogero Cammà; Gloria Taliani; Francesco Saverio Mennini
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

6.  DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsies.

Authors:  Emanuel Gonçalves; Maria Gonçalves-Reis; José B Pereira-Leal; Joana Cardoso
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

7.  Resource utilization and survival among Medicare patients with advanced liver disease.

Authors:  Munkhzul Otgonsuren; Linda Henry; Sharon Hunt; Chapy Venkatesan; Alita Mishra; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2014-08-10       Impact factor: 3.199

8.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

9.  A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.

Authors:  M Biselli; F Conti; A Gramenzi; M Frigerio; A Cucchetti; G Fatti; M D'Angelo; M Dall'Agata; E G Giannini; F Farinati; F Ciccarese; P Andreone; M Bernardi; F Trevisani
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

10.  Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.

Authors:  Wu Zhang; Cheng Guang Zhao; Hong Yu Sun; Wei E Zheng; Hua Chen
Journal:  Gut Liver       Date:  2014-07-25       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.